VYNE Therapeutics Inc. Annual Operating Income (Loss) in USD from 2015 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
VYNE Therapeutics Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2015 to 2023.
  • VYNE Therapeutics Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$13.1M, a 110% decline year-over-year.
  • VYNE Therapeutics Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$37.7M, a 24% decline year-over-year.
  • VYNE Therapeutics Inc. annual Operating Income (Loss) for 2023 was -$29.3M, a 14.7% increase from 2022.
  • VYNE Therapeutics Inc. annual Operating Income (Loss) for 2022 was -$34.3M, a 11.9% increase from 2021.
  • VYNE Therapeutics Inc. annual Operating Income (Loss) for 2021 was -$38.9M, a 84.6% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$29.3M +$5.04M +14.7% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-01
2022 -$34.3M +$4.62M +11.9% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-01
2021 -$38.9M +$214M +84.6% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-14
2020 -$253M -$157M -163% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-17
2019 -$95.9M -$21M -28% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-04
2018 -$74.9M -$45.3M -153% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-04
2017 -$29.6M -$15.3M -106% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-03
2016 -$14.3M -$9.72M -211% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-28
2015 -$4.61M Jan 1, 2015 Dec 31, 2015 10-K 2018-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.